Evaxion Biotech: 2026 Milestones & Showcase Presentation
The landscape of vaccine development is undergoing a significant change, driven by the integration of artificial intelligence. Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, is at the forefront of this revolution, pioneering AI-Immunology™ powered vaccines. As of January 7, 2026, the company is preparing to share key updates and future plans at the Biotech … Read more